These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25175966)

  • 1. Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease.
    Uchida S; Kadowaki-Horita T; Kanda T
    Int Rev Neurobiol; 2014; 119():169-89. PubMed ID: 25175966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.
    Kadowaki Horita T; Kobayashi M; Mori A; Jenner P; Kanda T
    Psychopharmacology (Berl); 2013 Dec; 230(3):345-52. PubMed ID: 23748382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical nonmotor aspect of A2A antagonist in PD treatment.
    Nomoto M; Nagai M; Nishikawa N
    Int Rev Neurobiol; 2014; 119():191-4. PubMed ID: 25175967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
    Kulisevsky J; Poyurovsky M
    Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
    Hirano S; Shinotoh H; Eidelberg D
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain.
    Giménez-Llort L; Schiffmann SN; Shmidt T; Canela L; Camón L; Wassholm M; Canals M; Terasmaa A; Fernández-Teruel A; Tobeña A; Popova E; Ferré S; Agnati L; Ciruela F; Martínez E; Scheel-Kruger J; Lluis C; Franco R; Fuxe K; Bader M
    Neurobiol Learn Mem; 2007 Jan; 87(1):42-56. PubMed ID: 16824773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the adenosine A
    Zhao Y; Zhou YG; Chen JF
    Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Istradefylline - a first generation adenosine A
    Jenner P; Mori A; Aradi SD; Hauser RA
    Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
    [No Abstract]   [Full Text] [Related]  

  • 14. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A; Pontis S; Borsini F; Morelli M
    Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting adenosine A2A receptors in Parkinson's disease.
    Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
    Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A(2A) adenosine receptors and Parkinson's disease severity.
    Casetta I; Vincenzi F; Bencivelli D; Corciulo C; Gentile M; Granieri E; Borea PA; Varani K
    Acta Neurol Scand; 2014 Apr; 129(4):276-81. PubMed ID: 24032478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.